Proportioned blood cardioplegia delivery systems- are you del iveri ng the [K+] you expect?

Abstract

This study was conducted to compare the actual potassium concentration [K+] delivered from a standard 4:1 ratio blood cardioplegia solution with the predicted [K+]. We found that the delivered [K+] ranged from 18.15 to 21.2 mEq/I although we predicted 22.0 mEq/I from our mathematical model. The factors that contributed to this difference were investigated. The ratio of blood:crystalloid was determined by: (1) potassium dilution technique; (2) volume output technique; and (3) from the manufacturer's tubing specifications and tolerances. This resulted in blood:crystalloid ratios of 3.86:1 (3.35-4.49:1), 3.74:1, and 4.0:1 (3.47-4.68:1), respectively. Analysis of the crystalloid component revealed an average [K+] of 75.7 mEq/I (70.0-81.5 mEq/I). Patient [K+] during the study ranged from 4.3 to 6.4 mEq/l. When the effect of clinical extremes in ratio, crystalloid [K+], and patient [K+] were considered, a range of cardioplegia [K+] of 16.0-24.3 mEq/I would be predicted. It was concluded that the ability to control the delivered [K+] with any precision is limited. Manufacturers should (1) match the tubing in such a way as to minimize ratio extremes and (2) adopt a tubing tolerance of ± 0.003 inches. Perfusionists should (1) analyse the crystalloid solution prior to cardiopulmonary bypass (CPB) and (2) analyse the cardioplegia [K+] when there is difficulty arresting the heart or if the patient [K+] is excessively elevated.

Get full access to this article

View all access options for this article.

References

Buckberg GR Strategies and logic of cardioplegia delivery to prevent, avoid, and reverse ischemic and reperfusion damage. J Thorac Cardiovasc Surg 1987; 93: 127-39.

Buckberg GD A proposed 'solution' to the cardioplegia controversy. J Thorac Cardiovasc Surg 1979;77:803-15.

Rosenkranz ER , Okamato F. , Buckberg GD , Vinten-Johansen J. , Robertson JM , Bugyi H. Safety of prolonged aortic clamping with blood cardioplegia. II: Glutamate enrichment in energy depleted hearts. J Thorac Cardiovasc Surg 1984; 88: 402-10.

Lichtenstein SV , Ashe KA , El Dalati H. , Cusimano RJ , Panos A. , Slutsky AS , Warm heart surgery. J Thorac Cardiovasc Surg 1991;101: 269-74.

Follette DM , Mulder DG , Maloney JV , Buckberg GD Advantages of blood cardioplegia over continuous coronary perfusion or intermittent ischemia - experimental and clinical study. J Thorac Cardiovasc Surg 1978; 76: 604-19.

Robertson JM , Buckberg, GD , Vinten-Johansen J. , Leaf JD Comparison of distribution beyond coronary stenoses of blood and asanguineous cardioplegia solutions . J Thorac Cardiovasc Surg 1983; 86: 80-86.

Bomfim V. , Kaijser L. , Bendy R. , Sylven C. , Olin C. Myocardial protection during aortic valve replacement. Scand J Thorac Cardiovasc Surg 1981; 15: 135-39.

Bodenheimer RM , De Boer Lwv , Geffin GA et al. Enhanced myocardial protection during ischemic arrest: oxygenation of a crystalloid cardioplegic solution. J Thorac Cardiovasc Surg 1983; 85: 769-80.

Vander Woude JC , Christlieb IY , Sicard GA , Clark RE Imidazole-buffered cardioplegia solution - improved myocardial protection during global ischemia. J Thorac Cardiovasc Surg 1985; 90: 225-34.

10.

Engelman RM , Awil J. , O'Donaghue MJ, Levitsky S. Significance of multidose cardioplegia and hypothermia in myocardial preservation during ischemic arrest. J Thorac Cardiovasc Surg 1978; 75: 555-62.

11.

Eng J. , Munsch C. Retrograde cardioplegia. Perfusion 1992; 7: 7-12.

12.

Solorzano J. , Taitelbaum G. , Chu-Jeng Chiu R. Retrograde coronary sinus perfusion for myocardial protection during cardiopulmonary bypass. Ann Thorac Surg 1978; 25: 201-208.

13.

Ruch TC , Patton HD Physiology and biophysics II. Philadelphia, London, Toronto: WB Saunders , 1974: 179.

14.

Tyers FO , Todd GJ , Niebauer IM , Manley NJ , Waldhausen JA The mechanism of myocardial damage following potassium citrate (Melrose) cardioplegia . Surgery 1975; 78: 45-53.